Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: Reuters Investment Profile
$20.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

KISSEI PHARMACEUTICAL CO LTD raises consolidated full-year forecast for FY 2014


Monday, 23 Dec 2013 07:00pm EST 

KISSEI PHARMACEUTICAL CO LTD:Sees revenue of 68,600 million yen, compared to its previous guidance of 65,500 million yen for the fiscal year ending Mar. 31, 2014.Sees operating profit of 11,400 million yen, compared to its previous guidance of 8,300 million yen.Sees ordinary profit of 12,700 million yen, compared to its previous guidance of 9,600 million yen.Sees net profit of 8,550 million yen, compared to its previous guidance of 6,450 million yen.Sees earning per share of 166.11 yen, compared to its previous guidance of 125.31.Says this is because the company has granted exclusive right of development and marketing of its gout and hyperuricemia treatment to Pfizer Inc. 

Company Quote

2692.0
19.0 +0.71%
22 Sep 2014